Original Article
European Journal of Clinical Nutrition (2007) 61, 54–60. doi:10.1038/sj.ejcn.1602475; published online 21 June 2006
Oral magnesium supplementation in asthmatic children: a double-blind randomized placebo-controlled trial
Guarantors: C Gontijo-Amaral and JD Ribeiro.
Contributors: CG-A conceived the idea and was responsible for study design, execution, data analysis and preparation of the paper. JDR coordinated and supervised the clinical trial. AC-N assisted with preparation of the paper and data analysis. LSCG assisted with preparation of the paper. MAGOR helped to perform pulmonary function tests.
C Gontijo-Amaral1, M A G O Ribeiro1, L S C Gontijo1, A Condino-Neto1,2 and J D Ribeiro1
- 1Department of Pediatrics and Center for Investigation in Pediatrics, State University of Campinas Medical School, Unicamp, Campinas, SP, Brazil
- 2Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil
Correspondence: Professor C Gontijo-Amaral, R. Marquis de maricá, 81 ap. 401, Santo Antònio, Belo Horizonte. MG, 30.350, Brazil and Department of Pediatrics and Center for Investigation in Pediatrics, CIPED, State University of Campinas Medical School, UNICAMP, Rua Pedro Natalino Zaghi, 80, Campinas, SP 13085.070, Brazil. E-mails: clesiogontijo@litoral.com.br, clesiogontijo@terra.com.br
Received 28 June 2005; Revised 17 January 2006; Accepted 27 March 2006; Published online 21 June 2006.
Abstract
Objective:
To investigate the long-term effect of oral magnesium supplementation on clinical symptoms, bronchial reactivity, lung function and allergen-induced skin responses in children and adolescents with moderate persistent asthma.
Design:
A double-blind randomized parallel placebo-controlled study.
Setting and subjects:
The patients were recruited from the Pediatric Outpatient Clinic, Division of Pulmonology, Allergy and Immunology, and followed at the Center for Investigation in Pediatrics at State University of Campinas Hospital, Brazil. Thirty-seven out of 72 patients met the study criteria. There were no dropouts.
Intervention:
The 37 patients (aged 7–19 years, 19 males) were randomized in two groups: magnesium (n=18, 300 mg/day) and placebo (n=19), during 2 months. Both patient groups received inhaled fluticasone (250 
g twice a day) and salbutamol as needed. The primary outcome was bronchial reactivity evaluated with methacholine challenge test (PC20).
Results:
After a follow-up of 2 months, the methacholine PC20 for testing bronchial reactivity has augmented significantly in the magnesium group only. The skin responses to recognized antigens have also decreased in patients treated with magnesium. The forced vital capacity (FVC), the forced expiratory volume at first second (FEV1), the forced expiratory flow at 25–75 and the FEV1/FVC ratio were similar in both groups. The magnesium group presented fewer asthma exacerbations and used less salbutamol compared to the placebo group.
Conclusions:
Oral magnesium supplementation helped to reduce bronchial reactivity to methacholine, to diminish their allergen-induced skin responses and to provide better symptom control in pediatric patients with moderate persistent asthma treated with inhaled fluticasone.
Keywords:
magnesium, asthma, allergy, bronchial reactivity, skin response, inhaled steroids
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
European Journal of Clinical Nutrition Original Article
Efficacy of magnesium in children with bronchial asthma
European Journal of Clinical Nutrition Letter
